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Recently, immune edition has been recognized as a new hallmark of cancer. In this respect, some clinical trials in breast cancer
have reported imppressive outcomes related to laboratory immune findings, especially in the neoadjuvant and metastatic setting.
Infiltration by tumor infiltrating lymphocytes (TIL) and their subtypes, tumor-associatedmacrophages (TAM) andmyeloid-derived
suppressive cells (MDSC) seem bona fide prognostic and even predictive biomarkers, that will eventually be incorporated into
diagnostic and therapeutic algorithms of breast cancer. In addition, the complex interaction of costimulatory and coinhibitory
molecules on the immune synapse and the different signals that they may exert represent another exciting field to explore. In this
review we try to summarize and elucidate these new concepts and knowledge from a translational perspective focusing on breast
cancer, paying special attention to those aspects that might have more significance in clinical practice and could be useful to design
successful therapeutic strategies in the future.
1. Introduction
Neoplasms represent a wide group of heterogeneous diseases
with several different alterations at genomic and proteomic
levels, which finally confer them the acquisition of the
neoplastic phenotype. Every human carcinoma induces an
immune response in its microenvironment. Generally, this
immune reaction is considered ineffective to destroy cancer
cells; however, in the last years evidence has emerged demon-
strating the importance of tumor lymphocyte infiltration in
the clinical evolution of many cancer types. Importantly, this
immune “awakening” against tumors may be induced by
some new and classical antineoplastic strategies. Hence, we
will analyze this new knowledge from a clinical point of view
focusing on breast cancer, giving eventual clues to overcome
and break immune tolerance in this disease.
2. Clinical Consequences of Immune-Related
Events in Breast Carcinoma
In the last few years, some translational studies in patients
with breast carcinoma have suggested that infiltration by
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tumor infiltrating lymphocytes (TIL) and regulatory T (Treg)
cells might have a great significance in the final clinical
outcomes.
In the neoadjuvant setting Demaria et al. found a change
in the frequency of TIL after treatmentwith paclitaxel. Impor-
tantly, response was correlated with TIL density suggesting
that apoptosis induced by taxanes is a powerful immunogenic
stimulus [1].
Recently, Denkert et al. investigated the hypothesis that
the presence of an intense lymphocytic infiltrate might
predict the response to neoadjuvant chemotherapy in breast
cancer [2]. They examined pretherapeutic core biopsies of
1058 patients enrolled in the GeparDuo and GeparTrio
studies. Results of these analyses showed that the presence
of intratumoral lymphocytes and lymphocyte-predominant
breast cancers were associated with a 31 and 41% pathological
complete response (pCR) rates, respectively [2]. On the
opposite, pCR rates were only 2% in patients without any
lymphocytic infiltration. In a multivariate analysis, intratu-
moral lymphocytes, age, and estrogen receptor status were
the only independent predictive parameters for pCR. Several
other studies have reported consistent data in the same
direction [3]. These results should not be overlooked as they
confirm a strong association between lymphocytic infiltrate
and chemotherapy response in a large set of more than 1000
samples of breast cancer.
Despite the impressive results achieved in the study
conducted by Denkert, TIL subtypes were not specifically
analyzed. On the contrary, Ladoire et al. reported another
interesting study conducted on 56 patients with operable
breast carcinoma and treated with preoperative chemother-
apy [4]. Overall, the histological analyses of surgical speci-
mens revealed a pathologic complete response in 21.4% of the
cases. pCRwas achieved in 40% of the tumors overexpressing
HER2 and only in 11% of the patients with HER2-negative
tumors. Results of T-cell infiltrates analyses were of great
interest at this point. After neoadjuvant chemotherapy CD3
and CD8 infiltrates remain stable, whereas FOXP3+ Treg
cell numbers significantly decreased in surgical specimens.
Importantly, pCR patients had a significantly lower number
of FOXP3 cells than nonresponders [4]. Accordingly with
this study, Perez et al. found that advanced breast cancer
patients with HER2+ tumors exhibited an overall signifi-
cantly increased frequency of circulating Treg, and, among
them, therapeutic intervention with trastuzumab led to an
overall reduction to normal levels in the frequency of Treg [5].
Remarkably, a good clinical response to trastuzumab therapy
was associated with a significant reduction in Treg frequency,
whereas disease recurrence correlated with a significant
increase in the percentage of circulating Treg [5].
Recently Mahmoud et al. analyzed the influence of
density of CD8+ cytotoxic lymphocytes on prognosis in a
large series of 1334 patients with primary invasive breast
carcinomas. CD8+ T cells were counted in three locations
per tumor (intratumoral compartment, adjacent, and distant
stroma), and the total number was determined by the sum
of the counts of these three compartments. Higher total
CD8+ lymphocyte counts were independently associated
with longer breast cancer specific survival after multivariate
analysis (Hazard Ratio, 0.55; 95% CI, 0.39-0.78; 𝑃 = 0.001) in
a model that included the standard prognostic and predictive
factors [6].
Taking into account the above mentioned studies
(Table 1), it is tempting to speculate that TIL infiltration may
represent not only a prognostic but rather a predictive factor
of clinical response in breast cancer, although prospective
validation studies are needed to confirm this hypothesis.
3. Regulatory T Lymphocytes and Host
Antitumor Response
Tumor infiltration by TIL is well recognized as a good
prognosis factor in multiple solid human neoplasms [7–10].
TIL are considered to be amanifestation of the host antitumor
reaction. However, there is growing evidence that the specific
type of immune cells rather than their quantity governs the
host-versus-tumor immune response.
The majority of TIL in solid tumors is CD3+ T-cell
phenotype. CD3 can be divided into CD4+ helper cells,
including Th1 and Th2 subtypes, based on their cytokine
profile, CD4+ regulatory T cells (Treg), and CD8+ cytotoxic
effector cells. Treg are thymus-derived CD4+CD25+ T lym-
phocytes that constitutively express cell surface cytotoxic T
lymphocyte antigen-4 (CTLA-4) and secrete immunosup-
pressive cytokines such as TGF-beta and IL-10 [11]. Treg may
also be induced in the periphery from na¨ıve T cells under
certain conditions, like stimulation with TGF-𝛽 [12].
Treg represent roughly 10% of CD4T cells and specifically
express the forkhead box P3 transcription factor (FOXP3)
[13, 14]. Recent studies have shown that Treg play an essential
role in sustaining self-tolerance by expressing a wide variety
of pathological immune responses against self, nonself, and
tumor antigens [11]. Although the exact mechanisms of Treg
suppression remain unknown, this effect seems to be largely
dependent on the expression of the transcription factor
FOXP3 which controls some genes encoding proteins like
CD25, GITR, CTLA-4, and others, capable of mediating Treg
suppressive functions [15, 16]. In addition, FOXP3 inhibits
production of effector cytokines like interleukin-2 (IL-2)
after T-cell receptor (TCR) stimulation of T cells [17]. Other
mechanisms of immunosuppression are direct cell-to-cell
contact with antigen presenting cells (APC) via transform-
ing growth factor 𝛽 (TGF-𝛽) or CTLA-4 and secretion of
immunosuppressive cytokines such as interleukin-10 (IL-10),
TGF-𝛽, and others [18, 19].
Specifically in breast carcinoma, the number of
FOXP3 CD4+CD25+ Treg and decreased ratios of CD8
T cells/FOXP3 Treg are correlated with a poor prognosis
[20]. Bates et al., after analyzing 222 breast carcinoma
specimens, observed that elevated numbers of Treg confer
a significantly shorter overall and recurrence-free survival
and that Treg quantity correlates significantly with more
aggressive breast cancer features (high tumor grade, node
positive disease) [20]. Although FOXP3 expression was
thought to be restricted to Treg, recently it has been
elucidated that this transcription factor is also present in
various types of tumor cells, including breast cancer [21–23].
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However, clinical implications of FOXP3 expression in breast
cancer cells are contradictory. Balsari et al. reported that
accumulation of FOXP3 Treg predicts a striking reduction of
patient survival [21]. On the contrary, Ladoire et al., in a large
prospective cohort of node positive breast cancer included
in the PACS01 trial, have recently reported better outcomes
for those patients that express FOXP3 in breast cancer cells
(37% of the entire population) but only in the group treated
without taxanes [22].The same group has published data of a
retrospective study restricted to a HER2-positive population
treated with neoadjuvant chemotherapy [23]. Again in this
case FOXP3 expression in tumor cells correlates with better
relapse free and overall survival. In line with these results,
FOXP3 has been recently demonstrated to be a tumor
suppressor gene that acts as a transcriptional repressor of
some breast cancer oncogenes [23].
As mentioned before, immune function is generally
compromised in cancer patients, which have lower absolute
numbers of peripheral blood lymphocytes but increased
numbers of functionally suppressive CD4+CD25+ Treg and
dysfunctional dendritic cells (DC) in peripheral blood and
tumor microenvironment [24]. In addition, higher numbers
of Treg in blood from patients with breast cancer have been
reported in relation to normal donors [25].
4. Mechanisms of Immune Tolerance:
Effects of Costimulatory and Coinhibitory
Molecules on the Immune Synapse
The immune synapse is a region of physical contact between
the T cell and the antigen presenting cell (APC), and it
represents one of the major determinants of the immune
response against tumoral antigens [26]. Two main signals are
required for an effective T-cell activation. The first signal is
provided by the recognition of cognate antigen bound major
histocompatibility complex (MHC) by the T-cell receptor
(TCR) [27]. Additional costimulatory signals are provided
by engagement of coreceptors. The canonical coreceptor
CD28 binds to members of the B7 family present on APC.
However, soon after T-cell priming, other negative regulatory
molecules are induced on T-cells leading to downregulation
of the T cell response. Some of the main costimulatory and
coinhibitory molecules that act as immune checkpoints on
the immune synapse are resumed in the following lines.
(a) CD40: CD40 is amember of the tumor necrosis factor
receptor family expressed on macrophages, dendritic
cells, endothelial and B cells, and fibroblasts [28].
Binding of CD40 with its CD40 ligand (CD40L)
or CD154 acts on APC and T cells mediating both
cellular and humoral responses. Specifically on APC,
CD40 plays a central role in priming and expansion
of antigen-specific CD4 T cells by regulating the
expression of costimulatory molecules on APC such
as CD80 and CD86 (B7.1 and B7.2) and by production
of cytokines such as IL-12, IL-8, or TNF-𝛼 [28, 29].
(b) Cytotoxic T lymphocyte antigen-4 (CTLA-4): CTLA-
4 acts as a key negative regulator of CD28 dependent
T-cell activation to limit self-damage [30]. CTLA-4
is produced and mobilized from the internal side of
the cell membrane, to the immune synapses 2 to 3
days after T-cell activation has taken place.There, it is
bound to either one of the costimulatory molecules,
CD80 and CD86. CTLA-4 expression turns the acti-
vated T cell to an inhibitory T cell [31]. A delay
in CTLA-4 expression favours T-cell activation and
could be a pathway to improve or expand the immune
response against tumors (Figure 1). Recently, an inter-
esting study analyzed the effect of CTLA-4 in breast
carcinoma [32]. CTLA-4 expression was detected in
breast tissue and blood of breast cancer patients and
normal donors. Patients showed strong expression of
CTLA-4 in tumor cells of all specimens. By contrast,
weakly positive or negative expression of CTLA-4was
found in normal breast tissue. In addition, patients
with highermRNA level of CTLA-4 had breast cancer
with worse features, and spontaneous expression of
CD3+CTLA-4+ on peripheral blood of patients with
tumors was also significantly higher than that of the
controls [32].
(c) Programmed death 1 (PD-1): PD-1 is expressed on
activated T and B cells, natural killer, dendritic cells,
and activatedmonocytes [33]. PD-1 plays a major role
inmaintenance of T-cell tolerance limiting effector T-
cell responses. There are two ligands of PD-1, PD-L1
and PD-L2 (or B7-H1 and B7-H2), although PD-L1
is considered the most important one [34]. PD-L1 is
aberrantly expressed in some tumors including breast
cancer, and thus it can induce immune suppression
through signaling PD-1 [35]. In breast cancer PD-L1
expression (in tumor tissue and TIL) has been shown
to be correlated with worsen clinicopathological data
like larger tumor size, histologic grade III tumors, or
negative hormone receptors [36].
(d) OX-40: OX-40 is a member of the tumor necrosis
factor (TNF) superfamily that needs T-cell activation
to be expressed [37]. OX-40 is present in CD4+ and
CD8+ T cells, whereas its ligand OX40L is expressed
on activated APC, B cells, and macrophages [38].
Binding of OX40 to the OX40L enhances prolif-
eration and survival of T cells leading to a larger
expansion of effector T and a larger pool of memory
T cells [37]. In addition, CD40 signaling increases
cytokine secretion by CD4+ T cells and enhances the
development of Th1 andTh2 cells [39].
The immune synapse is to be considered altogether as a
complex battlefield where many different molecules and
cells interact. It seems crucial to understand in depth the
mechanisms that may trigger a successful immune response
or on the contrary lead to immunotolerance at this level, in
order to find out emerging therapeutic tools targeting the
immune synapse.
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Table 1: Studies correlating immunobiomarkers with clinical results.
Study N (patients) Immunebiomarker Results
Balsari et al. [21]
DCIS: 62
Invasive: 257
Normal breast: 10
FOXP3
High FOXP3 in invasive and in situ breast carcinoma
than in normal breast
High FOXP3 shorter PFS and OS
Negative correlation between FOXP3 and ER
Ladoire et al. [4] 56
CD3
CD8
FOXP3
Poor prognostic factors (RE−, high-tumor grade and
nodal involvement) correlate with higher number of
FOXP3 before chemotherapy
>pCR to neoadjuvant chemotherapy correlates with
absence of FOXP3 cells and presence of high number of
CD8 T cell
Bates et al. [20] 183 + 214 FOXP3
FOXP3 expression in tumor associated with worse
overall survival
FOXP3 prognostic factor for distant metastases free
survival
Demaria et al. [1] 25 TIL Development of TIL after treatment correlates withclinical response to neoadjuvant chemotherapy
Denkert et al. [2] 1058 (2 cohort) TIL High TILs: pCR rates 42 and 40% versus 3 and 7%
Perez et al. [5]
24 normal breast
74 breast cancer
(28 HER−; 46
HER+)
Tregs
Treg frecuency in HER2+ was significantly increased.
Trastuzumab therapy: decreased Treg
frecuency/objective clinical response
Mahmoud et al. [6] 1334 CD8+ T TIL CD8+ density associated with improved clinicaloutcome
PFS: progression free survival; OS: overall survival; ER: estrogen receptor; and pCR: pathologic complete response.
5. Tumor-Associated Macrophages,
Myeloid-Derived Suppressor Cells, and
Related Cytokines
Chronic inflammation in some tissues correlates with
higher risk of developing cancer [40]. Within the tumoral
microenvironment, tumor-associated macrophages (TAM)
and myeloid-derived suppressive cells (MDSC) seem to play
a critical role in the progression of tumoral development
through nonimmune (mostly proangiogenic) and immune
mechanisms [41].
TAMs are a heterogeneous population of cells depending
on oxygen availability and phases of tumor development [42].
In early stages, tumors are generally infiltrated by type 1
macrophages (M1) that release proinflammatory cytokines
and chemokines promoting Th17 cell differentiation from
na¨ıve CD4+ T cells [43]. On the other hand, in advanced
stages, TAMs polarize to a type 2 macrophage (M2) related
cell that releases cytokines such as transforming growth
factors 𝛽1 (TGF 𝛽1) and IL-10, which induce Th2 differen-
tiation and recruitment, favouring Treg development and
thus promoting tumor development through inhibition of
anticancer immune responses [44].
In breast cancer, a sample of 128 matching invasive
(88% stages I-II) and ductal carcinomas in situ specimens,
along with normal breast tissues, was analyzed regard-
ing macrophage phenotype [45]. Increased M2-TAM was
significatively associated with more aggressive histopatho-
logical features (high tumor grade), increased microvessel
density, and decreased overall survival, whereas M1-TAM
phenotype was not associated with a worse overall survival.
Furthermore, M1-TAM tumors were predominantly low
grade [45].
MDSC represent a heterogeneous population of imma-
turemyeloid cells in different stages ofmyeloid cell differenti-
ation [46]. MDSC within the tumor microenvironment exert
a variety of immune suppressive functions by perturbing
both innate and adaptive immune responses.These effects are
largely dependent on cytokines (TGF-𝛽, IL-10, and IL-6) and
cellular factors observed in the surroundings of the tumors
[47]. Recently, Cole et al. demonstrated that circulating
MDSC inmetastatic breast cancer significantly correlate with
overall survival, observing worse outcomes in patients with
high percentages of MDSC (OS, 6.9 versus 19.6 months; 𝑃 =
0.05) [48].
These data suggest thatMDSCmight be a good biomarker
and even a therapeutic target in breast cancer.
As previously cited, cytokines are molecules of critical
importance in the tumor microenvironment that modulate
the activity of immune cells and may induce different
effects during tumor progression. Among immunosuppres-
sive cytokines the role of TGF-𝛽 and IL-10 merits special
consideration. Functions of both cytokines are intriguing and
complex as long as they seem to play initially and antitumor
effect preventing angiogenesis and inflammation by inhibit-
ing macrophage activation [43]. Nevertheless, in established
tumors, their effects are mostly protumorigenic, encouraging
cell survival, and suppressing effector T cells [43]. Specifically,
TGF-𝛽 plays a central role in the generation and function of
CD4+CD25+ Treg and suppression of IFN-𝛾 production by
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Figure 1: Role of CTLA-4 in T-cell activation. (1) CTLA-4 is a negative regulator of T-cell activation. (2) Conventional T cells are activated by
engagement ofMHCandB7. (3)Upon activation, T-cells express CTLA-4. Binding of CTLA-4with B7 inhibit T cell activation. (4) Blockade of
CTLA-4 produces the liberation of CD28 that engages with B7 activating T cells. APC: antigen presenting cell;MHC:major histocompatibility
complex; and TCR: T-cell receptor.
Th1 and CD8+ T cells, finally impeding a successful immune
response and favouring tumor progression [19, 49, 50].
However, there are also cytokines in the microenvi-
ronment like GM-CSF or IL-2 that exert costimulatory
effects [31]. GM-CSF has pleiotropic properties, including the
mobilisation, differentiation, and function of dendritic cells
[51], and it has also been studied in the clinical setting inmany
cancer types showing some promising results [52–54]. In this
sense, Honkoop et al. reported an interesting study in locally
advanced breast carcinoma treated with chemotherapy and
GM-CSF [54]. The authors reported a positive correlation
between the number of cycles received with GM-CSF and
overall survival (OS) and disease-free survival (DFS) [54].
One of the hypothesis to explain these results relies in the
large number of overexpressed tumoral antigens (Her-2/neu,
CEA, MUC-1, etc.) in breast cancer released after CT, which
represent an excellent target for an immune environment
boosted by GM-CSF [55].
6. Strategies to Overcome Immunotolerance in
Breast Cancer
6.1. Depletion of Treg. Depletion of FOXP3 Treg can enhance
antitumor immunity, and thus different strategies are being
pursued to attenuate the suppressive function of Treg [11].
Metronomic chemotherapy consists in administration of
low doses of chemotherapeuticals with the aim of reducing
tumor angiogenesis. Recently, it has been elucidated that low
doses of oral metronomic cyclophosphamide in advanced
cancer patients induce a profound and selective reduction of
circulating regulatory T cells, associated with a suppression
of their inhibitory functions on conventional T and NK cells,
therefore, leading to reduction of tumor-induced immune
tolerance and a better disease control [56, 57].
Treg are highly IL-2 dependent for their survival. IL-
2 neutralization with specific antibodies may substantially
reduce the number of Treg [58]. Denileukin diftitox (Ontak),
a recombinant fusion protein consisting of IL-2 and diph-
theria toxin, may deplete Treg and so reduce immune
suppression boosting antitumor immunity [58, 59]. CD25 is
the IL-2 receptor 𝛼 chain, so denileukin diftitox binds to the
IL-2 receptor and inhibits protein translation following inter-
nalization, leading to apoptosis [59]. Curiel demonstrated
in a phase 0/1 trial that Ontak at 9 or 12 𝜇g/kg decreased
the number of blood Treg and the suppression mediated
by the CD4+CD25+ blood T-cell population in patients
with advanced stage epithelial carcinomas, including cases of
breast carcinoma [60].
6.2. Immune Synapses as aTherapeutic Target. As mentioned
before, the immune synapses are virtual spaces where the
complex controls and checkpoints that modulate the interac-
tion of effector cells with their targets take place. Many of the
molecules and cells that compose the immune synapses are
attractive targets to be exploited clinically, and among them
CTLA-4 is probably the most widely studied molecule.
In preclinical studies with knockout mice it has been
reported that CTLA-4 deficiency in CD4+CD25+ Treg
impairs its suppressive function in tumor immunity [61, 62].
In addition, exclusive blockade of CTLA-4 signal in either
CD4+CD25+ Treg or nonTreg T cell in mice leads not only
to attenuation of Treg suppression but to augmentate effector
T-cell activity [61].
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A recent study demonstrated that antibodies against
CTLA-4 (anti-CTLA-4) induce proliferation of TCR stimu-
lated T effector cells and abrogate Treg suppressive activity by
enhancing IL-2 and IFN𝛾 release in response to polyclonal or
tumor antigen stimulation [63]. Curiously, anti-CTLA-4 does
not reduce the amount of Treg, suggesting that it mediates
immune responses by direct activation of T effector cells and
not by depleting Treg [63].
There are 2 CTLA-4 blocking antibodies for use in
humans [64]. Recently, ipilimumab (Bristol-Myers Squibb,
Princeton, JC, USA) has demonstrated significant benefits in
overall survival in randomized phase III studies in the first
or second line treatment of metastatic melanoma [65, 66],
gaining FDA approval.
Clinical research of anti-CTLA-4 in other solid neo-
plasms like breast carcinoma is scarce until now [67]. How-
ever a phase I study in advanced breast carcinoma with
the combination of exemestane and tremelimumab has been
recently reported, demonstrating that the combination is
well tolerated and associated with an increased expression
of inducible costimulator (ICOS+) in peripheral T CD4+
and CD8+ cells, which likely signals immune activation
secondary to CTLA-4 blockade [68].
A better understanding of the mechanism of action of
anti-CTLA-4, along with its use in the context of combi-
natorial strategies, may enable us to explore the eventual
efficacy of these molecules in nonmelanoma populations
[67, 69]. Combination of CTLA4 and PD-1 blockade with
anti-PD-1:B7-H1 monoclonal antibodies increases effector T-
cell infiltration into B16 melanoma in mice, resulting in an
elevated effector to Treg cell ratio within the tumor [70].
Phase I studies in humans with single agent anti-PD-1 in
refractory solid tumors have been performed with promising
results [71].
As previously cited, CD40 is another molecule that plays
an essential role in the immune synapses [35]. Several agonis-
tic antibodies against CD40 are under clinical research, and
preliminary data in murine models suggest strong immune
effects resulting in CD4 T-cell priming and cytotoxic T-
cell responses [72, 73]. Interestingly, a clinical study in
21 patients with advanced pancreatic carcinoma has been
recently reported testing the combination of gemcitabine
with CD40 agonist CP-870.893 [74]. Metabolic evaluation
by PET assessment revealed an impressive response rate of
88% after two cycles, with a median progression free and
overall survival of 5.6 and 7.4 months, respectively [74].
These interesting results deserve confirmation in phase II
and III studies. Again, preclinical data have revealed that
anti-CTLA-4 and CD40 are more effective when combined
that either therapy alone [75].
Finally, another immunogenic molecule is OX40. It is
elucidated that signaling throughOX40 andOX40L enhances
antitumor immunity [37]. In rodents, Murata et al. demon-
strated that combination of a GM-CSF secreting tumor cell
vaccine with anti-OX40 antibody induced a potent CD8+
T-cell response, leading to eradication of established breast
carcinomas [76]. This effect seems related to the prolonged
expansion and survival of tumor specific T cells. Another
interesting strategy relies in the combination ofOX40 therapy
with radiotherapy (RT) and/or chemotherapy. CT and RT
imply an enhanced expression of tumoral antigens with an
increase in tumor antigen-specific cytotoxicity and OX40
expression. Clinical trials testing this hypothesis are ongoing
[77, 78].
Although early in their clinical development, it is tempt-
ing to speculate that the universal mechanism of action
of anti-CTLA-4, anti-PD-1, and CD40 or OX-40 agonists,
among other molecules, may not only be restricted to
melanoma patients but rather may be useful in a wide
range of other oncologic diseases. Preclinical data support
clinical research in this field especially in the context of
combinatorial strategies. Likewise clinicians must be aware
that conventional response criteria seem no longer valid
in this context, and new guidelines for the evaluation of
immune-related responses must be considered [79].
6.3. Impact of Chemotherapy (CT) in Breast Cancer Microen-
vironment. Chemotherapy remains the therapeutical modal-
ity of choice for the systemic treatment of many breast
carcinomas, especially in the neoadjuvant and metastatic
setting. Impact of conventional chemotherapy on the rela-
tionship between the tumor and the immune system is
extremely important (Table 1). Some groups argue that cell
death induced by chemotherapy implies a variety of immune
reactions that mediate a sort of vaccination effect via release
of an “antigenicmilieu” that, in turn,may represent themajor
determinants of the therapeutical success of the chemother-
apy in oncological diseases [80].
Cytotoxic drugs destroy tumor cells by apoptosis [57],
and recent studies suggest that some chemotherapeutics may
induce tumoral destruction improving cancer cell recog-
nition by the immune system [81, 82]. Some preclinical
studies support the idea that immune stimulation might be
mediated by chemotherapy in murine cancer models treated
with gemcitabine and doxorubicin [83, 84]. The explanation
to this selective immune activation is an increased CD8
T-lymphocyte expansion and an increased density of TIL
mediated by an effective MHC class I cross-presentation of
tumor antigens released and phagocytosed [85].
There is now clear evidence supporting the fact that drugs
like anthracyclines, cyclophosphamide, or gemcitabine may
promote apoptosis in cancer cells with immunogenic effects
through several mechanisms [80, 85, 86] (Figure 2). This
sort of immunogenic tumor cell death is characterized by
a temporal sequence of events including early translocation
of calreticulin (CRT) to the cell surface and thereafter
interaction of CRT with multiple receptors on DC with
apoptotic bodies phagocytosis, release and exposure of heat
shock proteins, and late release of HMGB1 [85]. HMGB1
is able to bind to the TLR4 receptor on DC, which allows
tumor-derived antigens to be processed and presented along
with MHC and costimulatory molecules on the surface of
DC [58, 62]. These mechanisms altogether serve to trigger
DC-mediated specific antitumor response, which may be
enhanced by the use of costimulatory molecules [31].
In addition, other more general effects of chemotherapy
on the surrounding stroma are postulated like secondary
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Figure 2: Mechanisms of action of conventional antineoplastic agents and new immunostimulatory drugs.
necrosis or eradication of tumor cells [87]. Furthermore,
gemcitabine has demonstrated the ability to restore immune
surveillance by reducing MDSC levels in murine models,
which represents another interesting field to explore among
the immune effects of chemotherapy over microenvironment
[88].
In conclusion, emerging evidence led Lake and Robinson
to announce a paradigm shift in the way of understanding
the effects of CT on the surrounding stroma [87, 89]. These
new concepts may serve to consider chemotherapeutics as
less empirical and more specific drugs, thus may help to
customize treatments taking into account its potential effects
on the microenvironment.
7. Conclusions
Available data support the hypothesis of an immune-
mediated antitumor activity in breast carcinoma, and several
lines of research are ongoing [90]. It is critical to understand
what happens in the tumoral microenvironment in order
to design biological agents that may modulate the immune
response towards cancer cell destruction (Figure 2). Com-
bination strategies of chemoimmunotherapy will eventually
synergize and obtain meaningful clinical results.
Finally, the fact that probably themost successful strategy
in oncology in the last decade has been the combination
of chemotherapy and passive immunotherapy merits spe-
cial consideration. Rituximab and trastuzumab monoclonal
antibodies (MoAb) have obtained impressive results when
administered to the right populations [91, 92]. Interestingly
enough, the powerful effect of these MoAb is enhanced
when combined with chemotherapy, as a new evidence of the
priming of the APC tumor antigen presentation and T-cell
activation. Moreover, preclinical data exploring the effects
of a HER2/neu peptide vaccine combined with trastuzumab
have demonstrated synergistic immune enhancement [93].
8 Clinical and Developmental Immunology
In our opinion there is large amount of available data
which provides sufficient evidence to consider the host
immune reaction as one of the main determinants of the
clinical evolution in breast cancer. Importantly, this immune
response is capable of being modulated in clinical practice,
so new therapeutical strategies based on chemoimmunother-
apeutic approaches might be worthy of consideration in the
coming future to rise another step in the global battle against
breast cancer.
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